Neuroscience

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to…

7 months ago

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia King Faisal Specialist Hospital & Research…

8 months ago

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest

Curia & Carterra Biologics Symposium Biologics symposium slated for May 31 in Seattle, WA ALBANY, N.Y. and SALT LAKE CITY,…

8 months ago

Zeto Announces Expert Jury for Its EEG Clinical Trial Sponsorship Program

The selected clinical research projects will be publicly announced by June 10th, 2024SANTA CLARA, CA / ACCESSWIRE / May 7,…

8 months ago

Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

    Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities…

8 months ago

Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS

SIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has…

8 months ago

NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearanceMALVERN, Pa., May…

8 months ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim,…

8 months ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the…

8 months ago

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates…

8 months ago